Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valopicitabine in chronic hepatitis C
NCT00120861Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of valopicitabine in hepatitis C (HCV) (3 arms), sponsored by Merck & Co. Primary endpoints: Hepatitis C Virus Ribonucleic Acid at 24 weeks and Early Virologic Response at 12 weeks. Started Jan 2005; status: completed.
02
Drugs
valopicitabine
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00120861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00120861.